

02/02/01

11000 U.S. PTO
09/773510
02/02/01

General information		Demographic characteristics		Clinical characteristics		Treatment characteristics		Outcome characteristics	
Variable	Value	Variable	Value	Variable	Value	Variable	Value	Variable	Value
Study type	Retrospective	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study period	1990-2000	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study location	USA	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study population	1000	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study design	Cohort	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study objectives	Describe the prevalence of disease	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study limitations	Retrospective design	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study strengths	Large sample size	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study conclusions	Disease prevalence is high	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study implications	Need for further research	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study references	Smith et al. 2001	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study acknowledgments	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study funding	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study ethics	Approved	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study contact	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study publication	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study distribution	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study availability	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study access	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study use	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study citation	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study title	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study abstract	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study introduction	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study methods	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study results	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study discussion	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study conclusion	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study reference	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study acknowledgment	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study funding	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study ethics	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study contact	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study publication	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study distribution	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study availability	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study access	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study use	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study citation	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study title	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study abstract	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study introduction	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study methods	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study results	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study discussion	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male
Study conclusion	None	Age (years)	65.2	Sex	Female	Female	Female	Female	Female
Study reference	None	Age (years)	65.2	Sex	Male	Male	Male	Male	Male

1. This is a new ☒ **Utility** ☐ **Design** ☐ **Plant** patent application.
2. The papers enclosed to obtain a filing date are as follows:
 - 22 Pages of Specification including
 - 0 Title Page
 - 3 Pages of Claims
 - 1 Page of Abstract
 - 9 Sheets of drawings containing 20 Figures
 - ☐ The enclosed drawing(s) are photograph(s), and there is also attached a PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)
3. Combined Declaration and Power of Attorney
 - ☒ Enclosed and is executed by all inventors.
 - ☐ Not Enclosed.

This application is being filed under the provisions of 37 C.F.R. § 1.53(f).
Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the Declaration and paying the filing fees.

4. Language

☒ English

☐ Non-English

This application is being filed in accordance with 37 C.F.R. § 1.52(d) and § 608.01 of the MPEP. Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the verified English translation and the processing fee.

5. Assignment

☒ An assignment of the invention to Hamamatsu Photonics K.K. is enclosed.

☐ An assignment will be filed at a later date.

6. Priority - foreign applications under 35 U.S.C. § 119(a)-(d) or § 365(b) or PCT international applications under 35 U.S.C. § 365(a) designating at least one country other than the U.S.

☒ Priority of the following foreign applications is claimed:

Country	Application No.	Filed
Japan	10-231576	August 18, 1998

Certified copy(ies): ☒ is/are attached. ☐ will follow.

7. Priority based on an International Application

☒ Priority of the following international application under 35 U.S.C. § 365(c) is claimed:

Application No.	Filed
PCT/JP99/01603	March 29, 1999

A. Relate Back - 35 U.S.C. § 119(e)

☐ Amend the specification by inserting before the first line the sentence:
 "This application claims priority of copending provisional application(s)
 No. _____ filed on _____."

8. Small entity status

☐ A statement claiming small entity status under 37 C.F.R. §§ 1.9 and 1.27 is enclosed.

9. Fee Calculation (37 C.F.R. § 1.16)

CLAIMS FOR FEE CALCULATION				
	Number Filed	Number Extra	at Rate of	Basic Fee Utility \$710.00 Design \$320.00
Total Claims (37 C.F.R. § 1.16(c))	10 - 20 =	0	\$ 18.00 each=	\$
Independent Claims (37 C.F.R. § 1.16(b))	1 - 3 =	0	\$ 80.00 each=	\$
Multiple dependent claim(s), if any (37 C.F.R. § 1.16(d))			\$270.00	+
SUB-TOTAL =				\$710.00
Reduction by 1/2 for filing by a small entity				- \$
TOTAL FILING FEE =				\$710.00

10. Fee Payment

☐ Not Enclosed. **NO FEE IS BEING PAID BY CHECK OR DEPOSIT ACCOUNT AT THIS TIME.**
 This application is being filed under the provisions of 37 C.F.R. § 1.53(f).
 Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the Declaration and paying the filing fees.

[X] Enclosed.
Two checks in the amounts of \$710.00 and \$40.00 representing the basic filing fee (\$710.00) and recordation of Assignment fee (\$40.00) are enclosed.

11. [X] **Except** for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).


12. Additional papers enclosed:

- ☐ Preliminary Amendment
- ☒ Information Disclosure Statement
- ☒ International Search Report (second sheet)
- ☒ PTO Form-1449 and four (4) references
- ☒ Submission of Priority Document with certified copy JP 10-231576

Please accord this application an application number and filing date.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP



John G. Smith
Reg. No. 33,818

Dated: February 2, 2001

Customer No. 009629
MORGAN, LEWIS & BOCKIUS LLP
1800 M Street, N.W.
Washington, D.C. 20036
(202) 467-7000